Expert Interview
A Second Look: Examining the IPF treatment landscape with a focus on Pliant's bexotegrast, Fibrogen's pamrevlumab, and United Therapeutics' TYVASO (treprostinil)
Ticker(s): FGEN, PLRX, UTHRInstitution: National Jewish Health
- Associate Professor in the Department of Medicine and Clinic Director of the Interstitial lung disease(ILD) Program at National Jewish Health.
- Sub-investigator for the Phase II study for PLN 74809 as well as numerous other ILD/IPF studies being conducted at National Jewish Health.
- Research focuses on biomarkers in ILD and exercise limitation in post-COVID syndrome, with past research focused on investigating the role of angiogenesis in resolving lung injury and fibrosis.
How do each of these three treatments differ in their mechanism of action and do any of them stand out to you as a preferred method?
Added By: max_adminPliant Therapeutics is developing bexotegrast, which works on a different target from the approved drugs. What are your thoughts on this target and the data that they have generated so far?
What are your thoughts on bexotegrast target and the data that they have generated so far?
How would you describe the current standard of care, the available treatments and the unmet needs in this space?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
